Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("A.I.") and machine learning (“M.L.”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that it presented positive
preclinical data on the efficacy of its drug candidate LP-184 for
glioblastoma (GBM), used alone or in combination with the Food and
Drug Administration (FDA) approved agent spironolactone, at the
Society for Neuro-Oncology (SNO) annual meeting.
LP-184 is a small molecule drug candidate with a synthetically
lethal mechanism of action (MoA) that preferentially damages DNA in
cancer cells that harbor mutations in DNA damage repair (DDR) genes
and that overexpress the enzyme PTGR1. Lantern is developing LP-184
for several central nervous system cancers including GBM, which is
diagnosed in around 13,000 patients in the US annually and has an
estimated market potential of $1.5-2.0 billion.
“In our SNO poster, we demonstrated the exquisite in vitro/in
vivo efficacy of LP-184 towards GBM as a single agent or in
combination with spironolactone. LP-184 has the potential to become
a key therapeutic for the armamentarium for GBM, where the current
SOC agent Temozolomide (TMZ) can be ineffective in 50-70% of
patients,” stated Kishor Bhatia, Ph.D., Lantern’s Chief Scientific
Officer. “Our continued work with Johns Hopkins paves a path
forward for progressing LP-184 to the clinic for GBM where there is
an urgent and unmet need for novel therapeutics,” continued Dr.
Bhatia.
The SNO poster, which was presented in collaboration with John
Laterra, M.D., Ph.D., Co-Director of the Brain Cancer Program at
Johns Hopkins University, shows data supporting LP-184’s superior
anti-tumor efficacy over the current GBM SOC agent TMZ in GBM
preclinical models. In mice implanted with TMZ resistant GBM
patient derived xenografts, LP-184 was demonstrated to have an IC50
nanomolar potency of 209 nM, which was around 5,000X more potent
than TMZ. Additional preclinical findings in the poster demonstrate
that LP-184’s anti-tumor efficacy for GBM can be enhanced when
combined with spironolactone, an FDA approved agent that can
inhibit DDR mechanisms by degrading the protein ERCC3. Combining
LP-184 with spironolactone not only enhances LP-184’s potency, but
also has the potential to decrease the expected dose needed for
treatment in patients. These results continue to validate LP-184’s
potential as a promising therapeutic agent for GBM, which has had
no effective therapy developed in over 17 years.
LP-184 has been granted Orphan Drug Designation by the FDA for
the treatment of malignant gliomas, atypical teratoid rhabdoid
tumors (ATRT), and pancreatic cancer, and was also granted a Rare
Pediatric Disease Designation for ATRT. These designations and
continued positive preclinical data will help to accelerate LP-184
towards a targeted IND submission in Q1 2023 and first in human
Phase 1 clinical trials anticipated to commence in Q2 2023.
A full version of the poster presentation can be found on
Lantern’s website.
About Lantern’s LP-184 and Johns Hopkins
Collaboration:
Lantern and the research group of John Laterra, M.D., Ph.D., at
Kennedy Krieger Institute, which is affiliated with Johns Hopkins
University, initiated a research collaboration in 2020, which was
recently extended until the second half 2023, and has focused on
the development of LP-184 for several central nervous system
cancers (CNS) including GBM and brain metastases. The collaboration
has facilitated in identifying promising properties of LP-184 for
CNS cancers, which have included, favorable blood brain barrier
permeability, increased bioavailability in brain tumors compared to
normal brain tissues, and demonstrated efficacy in preclinical CNS
cancer models that are resistant to standard-of-care (SOC) agents.
Future research will aim at progressing LP-184 toward a first in
human Phase 1 clinical trial in early 2023 and identifying other
CNS cancers where LP-184’s MoA can be applied for therapeutic
benefit.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® A.I. and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
eleven disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes.
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221122005225/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma Monthly Newsletter: Sign-up here
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024